RMD Open

RMD Open is an online-only, open-access rheumatology journal published by BMJ and an official journal of the European Alliance of Associations for Rheumatology, launched in 2015, covering the full spectrum of rheumatic and musculoskeletal diseases, with a 2025 Journal Impact Factor of 5.3.《风湿病与肌肉骨骼疾病开放杂志》（RMD Open）是（BMJ）出版的纯在线开放获取风湿病学期刊，也是欧洲抗风湿病联盟（EULAR）的官方期刊，2015 年创刊，涵盖风湿病与肌肉骨骼疾病全领域，2025 年影响因子为 5.3。

Scope

• Rheumatoid arthritis and other inflammatory arthritides, including early disease and treatment strategies类风湿关节炎及其他炎性关节病，包括早期病变与治疗策略。
• Spondyloarthritis and psoriatic disease, from pathogenesis to clinical management脊柱关节炎与银屑病关节炎，从发病机制到临床处理。
• Connective tissue diseases including systemic lupus erythematosus, Sjogren syndrome, scleroderma and vasculitis结缔组织病，包括系统性红斑狼疮、（Sjogren）综合征、硬皮病与血管炎。
• Osteoarthritis, osteoporosis and other degenerative musculoskeletal conditions骨关节炎、骨质疏松及其他退行性肌肉骨骼疾病。
• Spinal disorders and rehabilitation, including exercise, physical therapy and outcome measurement脊柱疾病与康复，包括运动、物理治疗与结局评估。
• Clinical and epidemiological research, health services research and real-world evidence in rheumatology临床与流行病学研究、卫生服务研究以及风湿病领域的真实世界证据。
• Basic and translational medicine, plus interesting clinical cases and smaller studies that add to the literature基础与转化医学，以及有意义的临床病例和能够补充文献的小型研究。

History

• RMD Open was launched by BMJ in 2015 as an open-access companion to Annals of the Rheumatic Diseases and as an official journal of EULAR该刊由（BMJ）于 2015 年创办，是《风湿病学年鉴》的开放获取姊妹刊，同时是（EULAR）的官方期刊。
• The launch editorial by Maurizio Cutolo, Gerd R Burmester and Tore K Kvien set out EULAR's aims for the new title and the burden of rheumatic and musculoskeletal diseases in Europe由 Maurizio Cutolo、Gerd R Burmester 与 Tore K Kvien 撰写的创刊社论阐明了（EULAR）对新刊的定位，以及风湿病与肌肉骨骼疾病在欧洲造成的负担。^[1]
• Bernard Combe of CHU Lapeyronie in Montpellier, France, is credited as the founding editor（CHU Lapeyronie）的 Bernard Combe 被列为创刊主编。
• The journal is owned by BMJ, appears only online and publishes continuously rather than in discrete print issues期刊由（BMJ）所有，仅以在线形式出版，采用连续出版模式而非固定的纸本刊期。
• Articles are published open access under CC BY or CC BY-NC terms, with an article processing charge of GBP 3580论文以（CC BY）或（CC BY-NC）许可开放获取发表，版面费为 3580 英镑。
• It is indexed in Science Citation Index Expanded, MEDLINE, PubMed Central, Scopus, Embase and DOAJ, and its Journal Impact Factor rose from 5.117 in 2021 and 5.806 in 2022 to 4.7 in 2024 and 5.3 in 2025该刊被（Science Citation Index Expanded）、（MEDLINE）、（PubMed Central）、（Scopus）、（Embase）与（DOAJ）收录，影响因子由 2021 年的 5.117、2022 年的 5.806 变为 2024 年的 4.7 与 2025 年的 5.3。

Editors

• The editor-in-chief is Joao Eurico Fonseca of the University of Lisbon in Portugal现任主编为（University of Lisbon）的 Joao Eurico Fonseca，常驻葡萄牙里斯本。
• Bernard Combe, founding editor, remains listed with the journal at CHU Lapeyronie in Montpellier创刊主编 Bernard Combe 仍以（CHU Lapeyronie）的身份留在期刊编委名单中。
• Methodological and statistical advisers are Stian Lydersen of NTNU in Trondheim and Emilia Gvozdenovic of DESiRE Consulting in Mechelen, Belgium方法与统计顾问为（NTNU）的 Stian Lydersen 与（DESiRE Consulting）的 Emilia Gvozdenovic。
• Social media editors Shinji Izuka of the University of Tokyo, Cristiana Sieiro Santos of the University of Manchester and Vincenzo Venerito of the University of Bari Aldo Moro handle online dissemination社交媒体编辑为（University of Tokyo）的 Shinji Izuka、（University of Manchester）的 Cristiana Sieiro Santos 与（University of Bari Aldo Moro）的 Vincenzo Venerito，负责期刊的网络传播。
• Peer review is single anonymised, with reviewer identities hidden from authors, and the acceptance rate is about 20 percent该刊实行单盲评审，审稿人身份对作者保密，录用率约为 20%。
• Median times are 3 days to a first decision without review, 35 days with review, and 24 days from acceptance to publication首次决定的中位时间为 3 天（不经外审）或 35 天（经外审），录用至发表的中位时间为 24 天。